About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of highly selective Syk inhibitors, one of which is partnered with Ora Inc. Its Betrixaban is an oral once-daily inhibitor of Factor Xa. Its Andexanet alfa, is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor. The Company is developing orally available kinase inhibitors to treat hematologic disorders and inflammation.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: PTLA
- Previous Close: $32.14
- 50 Day Moving Average: $27.18
- 200 Day Moving Average: $22.36
- 52-Week Range: $15.68 - $33.28
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -9.45
- P/E Growth: 0.00
- Market Cap: $1.82B
- Outstanding Shares: 56,543,000
- Beta: 1.24
- Net Margins: -1,072.67%
- Return on Equity: -82.19%
- Return on Assets: -66.51%
Companies Related to Portola Pharmaceuticals:
- Current Ratio: 6.36%
- Quick Ratio: 6.36%
What is Portola Pharmaceuticals' stock symbol?
Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA."
Where is Portola Pharmaceuticals' stock going? Where will Portola Pharmaceuticals' stock price be in 2017?
7 equities research analysts have issued 1-year target prices for Portola Pharmaceuticals' stock. Their predictions range from $27.00 to $40.00. On average, they anticipate Portola Pharmaceuticals' stock price to reach $32.00 in the next year.
When will Portola Pharmaceuticals announce their earnings?
Portola Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, February, 24th 2017.
Who owns Portola Pharmaceuticals stock?
Portola Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Temasek Holdings Private Ltd (11.64%), Deerfield Management Co. (8.23%), FMR LLC (6.54%), State Street Corp (3.57%), Orbimed Advisors LLC (0.98%) and Pinnacle Associates Ltd. (0.97%). Company insiders that own Portola Pharmaceuticals stock include Charles J Homcy, Fullerton Management Pte Ltd, Hollings Renton, John T Curnutte, Mardi Dier and William Lis.
Who sold Portola Pharmaceuticals stock? Who is selling Portola Pharmaceuticals stock?
Portola Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Deerfield Management Co., Oxford Asset Management, FMR LLC, Pinnacle Associates Ltd., Guggenheim Capital LLC, Martingale Asset Management L P and Ladenburg Thalmann Financial Services Inc..
Who bought Portola Pharmaceuticals stock? Who is buying Portola Pharmaceuticals stock?
Portola Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, State Street Corp, Pacad Investment Ltd., Nicholas Investment Partners LP, Highland Capital Management LP, Ellington Management Group LLC and State Board of Administration of Florida Retirement System.
How do I buy Portola Pharmaceuticals stock?
Shares of Portola Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Portola Pharmaceuticals stock cost?
One share of Portola Pharmaceuticals stock can currently be purchased for approximately $32.14.